Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tysabri Cohort Study May Need Internal Control Group For Useful Results

Executive Summary

A 5,000-patient observational cohort study included in Tysabri's risk management plan for return to market may need an internal control group to provide useful results, members of FDA's Peripheral & Central Nervous System Drugs Advisory Committee indicated March 8

You may also be interested in...

Tysabri Out Of Remission; Returns With Updated Indication, Risk Management

The indication for Biogen Idec/Elan's re-approved multiple sclerosis therapy Tysabri (natalizumab) stops short of limiting it to use as a second-line therapy

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts